(Total Views: 470)
Posted On: 04/27/2024 9:41:00 PM
Post# of 155802
Wouldn't that be using the costs associated to the current pharma model?
LL will remove costs up n down, rooter to the tooter, a running of the gamut. From so many aspects of developing costs, until it's to a doctor.
Totally new model.
My thinking was a powerful consortium spending the say couple hundred million, for a few trials as needed, shocking the world. Gaining acceptance
After that, the industry workings will understand LL is the future & welcome Cytodyn as a client.
If a powerful group formed, they wouldn't spend their cash.
FDA now will be faced with good trial design / data.
Hard to delay based on that now, post hold removed.
Actually, easiest approval for them in their history.
Going to stick with they're not a roadblock to LL.
Quick thought is, the distributing to doctors only through pharma, can be overcome if chosen --- in comparison, LL even has ease of storage
LL will remove costs up n down, rooter to the tooter, a running of the gamut. From so many aspects of developing costs, until it's to a doctor.
Totally new model.
My thinking was a powerful consortium spending the say couple hundred million, for a few trials as needed, shocking the world. Gaining acceptance
After that, the industry workings will understand LL is the future & welcome Cytodyn as a client.
If a powerful group formed, they wouldn't spend their cash.
FDA now will be faced with good trial design / data.
Hard to delay based on that now, post hold removed.
Actually, easiest approval for them in their history.
Going to stick with they're not a roadblock to LL.
Quick thought is, the distributing to doctors only through pharma, can be overcome if chosen --- in comparison, LL even has ease of storage
(1)
(0)
